Structural myocardial reorganization and changes in the blood lipid spectrum in rats were studied after administration of a single sublethal dose of doxorubicin (15 mg/kg) alone and in combination with atorvastatin (20 mg/kg/day over 7 days). It was established that doxorubicin induced the development of dyslipidemia in experimental animals (the concentrations of total cholesterol, triglycerides, and VLDL increased by 2.2, 2.0, and 1.96 times, respectively; the atherogenic coefficient increased by 3.4 times by day 7 of the experiment). In animals with experimental anthracycline cardiomyopathy treated with atorvastatin, the concentrations of the main components of the blood lipid spectrum increased less markedly. Atorvastatin alone induces moderate myocardial remodeling in comparison with more pronounced changes in the structural organization of the myocardium in rats treated with doxorubicin alone. Course treatment with atorvastatin under conditions of doxorubicin-induced cardiomyopathy reduced the severity of myocardial remodeling: the decrease in the volume density of cardiomyocytes and the increase in the volume density of the connective tissue were less pronounced in the dynamics of the experiment.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
Tax calculation will be finalised during checkout.
Klinnikova MG, Lushnikova EL, Koldysheva EV, Tolstikova TG, Sorokina IV, Yuzhik EI, Mzhelskaya MM. Cardiotoxic and Dyslipidemic Effects of Doxorubicin and Betulinic Acid Amide. Bull. Exp. Biol. Med 2016;162(2):277-282. https://doi.org/10.1007/s10517-016-3594-9
Lushnikova EL, Molodykh OP, Nikityuk DB, Semenov DE, Klinnikova MG. Structural Analysis of the Myocardium in Experimental Anthracycline-Induced Cardiomyopathy Combined with Adrenergic Stimulation. Bull. Exp. Biol. Med. 2019;166(5):689-694. https://doi.org/10.1007/s10517-019-04419-x
Birnbaum GD, Birnbaum I, Ye Y, Birnbaum Y. Statin-Induced Cardioprotection Against Ischemia-Reperfusion Injury: Potential Drug-Drug Interactions. Lesson to Be Learnt by Translating Results From Animal Models to the Clinical Settings. Cardiovasc. Drugs Ther. 2015;29(5):461-467. https://doi.org/10.1007/s10557-015-6615-4
Henriksen PA. Anthracycline Cardiotoxicity: An Update on Mechanisms, Monitoring and Prevention. Heart. 2018;104(12):971-977. https://doi.org/10.1136/heartjnl-2017-312103
Kim YH, Park SM, Kim M, Kim SH, Lim SY, Ahn JC, Song WH, Shim WJ. Cardioprotective Effects of Rosuvastatin and Carvedilol on Delayed Cardiotoxicity of Doxorubicin in Rats. Toxicol. Mech. Methods. 2012;22(6):488-498. https://doi.org/10.3109/15376516.2012.678406
McGowan JV, Chung R, Maulik A, Piotrowska I, Walker JM, Yellon DM. Anthracycline Chemotherapy and Cardiotoxicity. Cardiovasc. Drugs. Ther. 2017;31(1):63-75. https://doi.org/10.1007/s10557-016-6711-0
Mitry MA, Edwards JG. Doxorubicin induced heart failure: Phenotype and molecular mechanisms. Version 2. Int. J. Cardiol. Heart Vasc. 2016;10:17-24. https://doi.org/10.1016/j.ijcha.2015.11.004
Nagaoka K, Matoba T, Mao Y, Nakano Y, Ikeda G, Egusa S, Tokutome M, Nagahama R, Nakano K, Sunagawa K, Egashira K. A New Therapeutic Modality for Acute Myocardial Infarction: Nanoparticle-Mediated Delivery of Pitavastatin Induces Cardioprotection from Ischemia-Reperfusion Injury via Activation of PI3K/Akt Pathway and Anti-Inflammation in a Rat Model. PLoS One. 2015;10(7):e0132451. https://doi.org/10.1371/journal.pone.0132451
Ramasubbu K, Estep J, White DL, Deswal A, Mann DL. Experimental and Clinical Basis for the Use of Statins in Patients with Ischemic and Nonischemic Cardiomyopathy. J. Am. Coll. Cardiol. 2008;51(4):415-426. https://doi.org/10.1016/j.jacc.2007.10.009
Sharma H, Pathan RA, Kumar V, Javed S, Bhandari U. Antiapoptotic Potential of Rosuvastatin Pretreatment in Murine Model of Cardiomyopathy. Int. J. Cardiol. 2011;150(2):193-200. https://doi.org/10.1016/j.ijcard.2010.04.008
Yu Y, Jin L, Zhuang Y, Hu Y, Cang J, Guo K. Cardioprotective effect of rosuvastatin against isoproterenol-induced myocardial infarction injury in rats. Int. J. Mol. Med. 2018;41(6):3509-3516. https://doi.org/10.3892/ijmm.2018.3572
Zacà V, Rastogi S, Imai M, Wang M, Sharov VG, Jiang A, Goldstein S, Sabbah HN. Chronic Monotherapy With Rosuvastatin Prevents Progressive Left Ventricular Dysfunction and Remodeling in Dogs With Heart Failure. J. Am. Coll. Cardiol. 2007;50(6):551-557. https://doi.org/10.1016/j.jacc.2007.04.050
Zhang L, Cheng L, Wang Q, Zhou D, Wu Z, Shen L, Zhang L, Zhu J. Atorvastatin Protects Cardiomyocytes From Oxidative Stress by Inhibiting LOX-1 Expression and Cardiomyocyte Apoptosis. Acta Biochim. Biophys. Sin. (Shanghai). 2015;47(3):174-182. https://doi.org/10.1093/abbs/gmu131
Translated from Byulleten’ Eksperimental’noi Biologii i Meditsiny, Vol. 170, No. 7, pp. 33-39, July, 2020
About this article
Cite this article
Klinnikova, M.G., Koldysheva, E.V., Tursunova, N.V. et al. Features of Myocardial Remodeling and Changes in the Blood Lipid Spectrum in Experimental Doxorubicin-Induced Cardiomyopathy and Atorvastatin Administration. Bull Exp Biol Med (2020). https://doi.org/10.1007/s10517-020-04997-1
- blood lipid spectrum